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A B S T R A C T
Objectives: Many patients with squamous cell carcinoma of the head and neck (SCCHN) are ≥65 years old;
comorbidities and other age-related factors may affect their ability to tolerate traditional chemotherapy.
Nivolumab is the only immunotherapy to significantly improve overall survival (OS) versus investigator’s choice
(IC) of single-agent chemotherapy at primary analysis in a phase 3 trial (CheckMate 141) in patients with
recurrent/metastatic SCCHN post-platinum therapy. In this post hoc analysis, we report efficacy and safety by
age.
Patients and methods: Eligible patients were randomized 2:1 to nivolumab 3mg/kg every 2 weeks (n=240) or
IC (methotrexate, docetaxel, or cetuximab n=121). The primary endpoint of the trial was OS. For this analysis,
outcomes were analyzed by age < 65 and ≥65 years. The data cut-off date was September 2017 (minimum
follow-up 24.2months).
Results: At baseline, 68 patients (28.3%) receiving nivolumab and 45 patients (37.2%) receiving IC were
≥65 years. Baseline characteristics were generally similar across age groups. OS and tumor response benefits
with nivolumab versus IC were maintained regardless of age. The 30-month OS rates of 11.2% (<65 years) and
13.0% (≥65 years) with nivolumab were more than tripled versus corresponding IC rates of 1.4% and 3.3%,
respectively. The nivolumab arm had a lower rate of treatment-related adverse events versus IC regardless of
age, consistent with the overall patient population.
Conclusion: In CheckMate 141, nivolumab resulted in a higher survival versus IC in patients< 65 and
≥65 years, with a manageable safety profile in both age groups.
ClinicalTrials.gov: NCT02105636.
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Introduction
Over half of the 500,000 new cases of squamous cell carcinoma of
the head and neck (SCCHN) worldwide occur in patients 65 years of age
and older [1,2], and this is expected to increase as the population ages
[3,4]. A high proportion of cases will go on to develop recurrent/me-
tastatic disease [5,6], for which platinum-based chemotherapy with or
without cetuximab or pembrolizumab can be used as first-line therapy
for patients able to tolerate treatment [7–9].
Immune checkpoint inhibitors are a recent treatment strategy for
patients with SCCHN and offer an opportunity for durable responses
with a manageable safety profile [2]. Two programmed death-1 (PD-1)
inhibitors, nivolumab and pembrolizumab, are currently approved for
the treatment of patients with recurrent/metastatic SCCHN who ex-
perienced disease progression after platinum-based therapy. However,
there are concerns that age-related decline in immune function may
impact the activity of checkpoint inhibitors [10,11]. Some data have
been reported for these agents in elderly patients with other solid tu-
mors [11,12], and a recent publication of pembrolizumab in recurrent/
metastatic SCCHN post-platinum therapy included limited data on ef-
ficacy by age [13].
At the primary analysis of the randomized, open-label, phase 3
CheckMate 141 trial (NCT02105636), nivolumab significantly im-
proved overall survival (OS) versus investigator’s choice (IC) of therapy
in patients with recurrent/metastatic SCCHN who experienced tumor
progression or recurrence within 6months of platinum-based therapy
administered in the adjuvant, primary (i.e. with radiation), recurrent,
or metastatic setting; survival benefit was maintained at 1 and 2 years
of follow-up irrespective of tumor programmed death ligand 1 (PD-L1)
expression and human papillomavirus (HPV) status [14–16]. The safety
profile of nivolumab was manageable, with fewer grade 3–4 treatment-
related adverse events (TRAEs) compared with IC [15]. Here, we report
a post hoc analysis of the efficacy and safety of nivolumab by age (< 65
and ≥65 years old) in patients with recurrent/metastatic SCCHN from
CheckMate 141.
Patients and methods
Study design and patients
CheckMate 141 is a randomized, open-label, phase 3 trial; the de-
tailed study design has been described previously [14]. Briefly, eligible
patients were 18 years of age or older, had histologically confirmed,
recurrent/metastatic SCCHN of the oral cavity, oropharynx, hypo-
pharynx, or larynx, and had tumor progression on or within 6months
after the last dose of platinum-based chemotherapy administered in the
locally advanced, recurrent, or metastatic disease setting. Patients were
randomized 2:1 to receive nivolumab (3mg/kg every 2 weeks) or
standard single agent of IC (methotrexate 40–60mg/m2 weekly, doc-
etaxel 30–40mg/m2 weekly, or cetuximab 400mg/m2 once, then
250mg/m2 weekly) and stratified by prior cetuximab treatment.
Treatment continued until tumor progression or unacceptable toxicity.
Patients in the nivolumab arm were allowed to continue nivolumab
treatment beyond tumor progression if they met predefined, protocol-
specified criteria [15].
CheckMate 141 was conducted in accordance with the ethical
principles in the Declaration of Helsinki. Written informed consent was
obtained from all patients prior to enrollment. The study was approved
by the institutional review board or independent ethics committee at
each center and was conducted in accordance with Good Clinical
Practice guidelines defined by the International Conference on
Harmonisation.
Outcomes
The primary endpoint was OS, defined as the time from randomi-
zation to death due to any cause. Progression-free survival (PFS), de-
fined as the time from randomization to first date of investigator-as-
sessed progression, and objective response rate (ORR), defined as the
proportion of randomized patients who achieved a best response of
complete or partial response as per investigator assessment, were sec-
ondary endpoints; duration of objective response, defined as time from
objective response until a progression event, was an exploratory end-
point. Tumor responses were evaluated every 6 weeks from week 9
until disease progression or treatment discontinuation using Response
Evaluation Criteria in Solid Tumors (RECIST) v1.1 [17]. Safety was
evaluated using the Common Terminology Criteria for Adverse Events,
version 4.0, at each treatment visit and for 100 days after receipt of last
dose. Adverse events with potential immunologic cause were char-
acterized as select adverse events. Tumor PD-L1 expression and HPV
status were assessed as previously described [14].
For this post hoc subgroup analysis, outcomes were analyzed by age
(< 65 years and ≥65 years). This analysis is based on a September
2017 data cutoff, representing a minimum follow-up of 24.2months
(Supplementary Fig 1.).
Fig. 1. Overall survival (OS) in patients (A)< 65 years old and (B) ≥65 years old. Abbreviations: CI= confidence interval; HR=hazard ratio; IC= investigator’s
choice; NIVO=nivolumab.
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Statistical analyses
Efficacy analyses were conducted in patients< 65 and ≥65 years
old in the intent-to-treat population; safety analyses were conducted in
the same subgroups among patients who received at least one dose of
treatment.
OS and PFS were estimated by the Kaplan-Meier method [18]; Cox
proportional hazards models were used to estimate hazard ratios and
corresponding two-sided 95% confidence intervals (CIs). A general-
ization of the Brookmeyer and Crowley method with a log-log trans-
formation was used to compute CIs for median survival times [19], and
a two-sided Cochran-Mantel-Haenszel test was used to compute the
odds ratio and corresponding CIs for tumor response [20,21].
BMS policy on data sharing may be found at https://www.bms.
com/researchers-and-partners/independent-research/data-sharing-
request-process.html.
Results
Patients and treatment
Of the 361 patients who underwent randomization, 68 of 240 pa-
tients in the nivolumab arm (28.3%) and 45 of 121 in the IC arm
(37.2%) were ≥65 years old; 31 (12.9%) and 23 patients (19.0%), re-
spectively, were ≥70 years old. Baseline characteristics were generally
similar between patients< 65 years and ≥65 years old; notably, per-
centages of prior systemic therapy received were evenly matched be-
tween groups (Table 1).
Relative dosing intensity was comparable between the two age
groups (< 65 and ≥65 years old) in the nivolumab arm
(Supplementary Table 1). Median duration of therapy was similar be-
tween age groups in both the nivolumab and IC arms (1.6–1.9months).
Survival
Nivolumab resulted in a higher median OS compared with IC in
patients< 65 years old (8.2 vs. 4.9months, HR 0.63; 95% CI
0.47–0.84) and in patients≥65 years old (6.9 vs. 6.0 months; HR 0.75;
95% CI 0.51–1.12; Fig. 1). Estimated OS rates at 12 months were higher
in the nivolumab arms compared with IC in both age groups: 33.3%
(95% CI 26.2–40.4) versus 19.7% (95% CI 11.5–29.6) in patients<
65 years old and 34.6% (95% CI 23.5–45.9) versus 20.0% (95% CI
9.9–32.6) in patients ≥65 years old. Similar results were observed at
30months: OS rates with nivolumab were 11.2% (95% CI 6.7–16.9) in
patients< 65 years old and 13.0% (95% CI 6.2–22.5) in patients
≥65 years old; corresponding rates with IC were 1.4% (95% CI 0.1–6.7)
and 3.3% (95% CI 0.3–13.2), respectively. OS benefit with nivolumab
was maintained irrespective of tumor PD-L1 expression levels and HPV
status (Fig. 2) across both age groups.
Median PFS was similar in both treatment arms for patients< 65
years old (nivolumab, 2.0 months; IC, 2.7 months; HR 0.96; 95% CI
0.71–1.30) and for patients ≥65 years old (nivolumab, 2.1months; IC,
2.0 months; HR 0.74; 95% CI 0.49–1.11), consistent with results in the
overall study population (Fig. 3).
Best overall response
Treatment with nivolumab resulted in higher ORR versus IC in both
age groups (Table 2). In patients< 65 years old, ORRs for the nivo-
lumab and IC arms were 12.8% and 6.6%, respectively; in patients
≥65 years old, ORRs were 14.7% and 4.4%, respectively, including
three patients (4.4%) with complete responses and seven patients
(10.3%) with partial responses in the nivolumab arm (Fig. 4). Among
patients ≥65 years old receiving IC, 1 patient (2.2%) had a complete
response and 1 patient (2.2%) had a partial response. Median duration
of objective response in the nivolumab arm was 8.5months for
patients< 65 years old and was not reached for patients≥65 years old.
Safety
TRAEs are summarized in Table 3. Among patients< 65 years old,
any grade and grade 3–4 TRAEs were reported in 63.7% and 16.1% of
patients receiving nivolumab, respectively, and in 77.5% and 31.0% of
patients receiving IC, respectively. Among patients who were
Table 1
Baseline characteristics. aSome patients may have been treated with more than
one type of therapy. Abbreviations: ECOG=Eastern Cooperative Oncology
Group; HPV=human papillomavirus; IC= investigator’s choice; PD-
L1=programmed death ligand 1.
Patients, n (%) < 65 Years ≥65 Years
Nivolumab
(n= 172)
IC (n=76) Nivolumab
(n=68)
IC (n= 45)
Sex, male 134 (77.9) 67 (88.2) 63 (92.6) 36 (80.0)
Race
White 139 (80.8) 66 (86.8) 57 (83.8) 38 (84.4)
Black or African
American
8 (4.7) 2 (2.6) 2 (2.9) 1 (2.2)
Asian 20 (11.6) 8 (10.5) 9 (13.2) 6 (13.3)
Other 5 (2.9) 0 0 0
ECOG performance
status
0 40 (23.3) 16 (21.1) 9 (13.2) 7 (15.6)
1 132 (76.7) 56 (73.7) 57 (83.8) 38 (84.4)
≥2 0 3 (3.9) 1 (1.5) 0
Not reported 0 1 (1.3) 1 (1.5) 0
Region
North America 76 (44.2) 28 (36.8) 25 (36.8) 16 (35.6)
Europe 75 (43.6) 39 (51.3) 34 (50.0) 23 (51.1)
Rest of world 21 (12.2) 9 (11.8) 9 (13.2) 6 (13.3)
Tobacco use
Current/former 135 (78.5) 57 (75.0) 56 (82.4) 29 (64.4)
Never 28 (16.3) 17 (22.4) 11 (16.2) 14 (31.1)
Unknown 9 (5.2) 2 (2.6) 1 (1.5) 2 (4.4)
Site of primary tumor
Oral cavity 85 (49.4) 42 (55.3) 23 (33.8) 25 (55.6)
Pharynx 66 (38.4) 24 (31.6) 26 (38.2) 13 (28.9)
Larynx 18 (10.5) 8 (10.5) 16 (23.5) 6 (13.3)
Other 3 (1.7) 2 (2.6) 3 (4.4) 1 (2.2)
HPV status
Positive 45 (26.2) 18 (23.7) 19 (27.9) 11 (24.4)
Negative 38 (22.1) 23 (30.3) 18 (26.5) 14 (31.1)
Unknown/not
reported
89 (51.7) 35 (46.1) 31 (45.6) 20 (44.4)
PD-L1 expression
≥1% 71 (41.3) 37 (48.7) 25 (36.8) 26 (57.8)
< 1% 49 (28.5) 31 (40.8) 27 (39.7) 9 (20.0)
Lines of prior
systemic cancer
therapy
1 73 (42.4) 33 (43.4) 33 (48.5) 25 (55.6)
2 62 (36.0) 31 (40.8) 18 (26.5) 13 (28.9)
≥3 37 (21.5) 12 (15.8) 17 (25.0) 7 (15.6)
Prior systemic
therapy
receiveda
Platinum-based
therapy
172 (100.0) 76 (100.0) 68 (100.0) 45 (100.0)
Monoclonal
antibody
113 (65.7) 45 (59.2) 40 (58.8) 28 (62.2)
Folic acid analog 5 (2.9) 3 (3.9) 2 (2.9) 0
Taxane 97 (56.4) 41 (53.9) 35 (51.5) 21 (46.7)
Other – approved 107 (62.2) 51 (67.1) 33 (48.5) 18 (40.0)
Other –
experimental
19 (11.0) 7 (9.2) 4 (5.9) 7 (15.6)
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≥65 years old, any grade and grade 3–4 events were reported in 57.4%
and 13.2%, respectively, of patients receiving nivolumab, and in 82.5%
and 47.5%, respectively, of patients receiving IC. The most common
select TRAEs in patients≥65 years old in the nivolumab arm were skin-
related (14 patients; 20.6%); no grade 3–4 select TRAEs were reported
in this patient subgroup (Supplementary Table 2).
Efficacy and safety among patients ≥70 years old
In patients ≥70 years old (nivolumab, n= 31; IC, n=23), the
efficacy of nivolumab treatment was consistent with that seen in pa-
tients ≥65 years old and in the overall patient population; median OS
in this group was 4.8 months in the nivolumab arm compared with
4.6 months in the IC arm (HR 0.91; 95% CI 0.52–1.60). Median PFS was
2.1 months in the nivolumab arm compared with 2.3 months in the IC
arm (HR 1.0; 95% CI 0.57–1.75). Among patients who were≥70 years
old, ORRs in the nivolumab and IC arms were 6.5% and 8.7%, re-
spectively. Any grade and grade 3–4 TRAEs were reported in 48.4% and
9.7%, respectively, of patients receiving nivolumab, and in 81.0% and
52.4%, respectively, of patients receiving IC.
Fig. 2. Overall survival (OS) by (A, B) tumor programmed death ligand 1 (PD-L1) expression and (C, D) human papillomavirus (HPV) status.
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Discussion
In this post hoc analysis from CheckMate 141, the threshold of
65 years of age was chosen to maintain an optimal number of patients
in each treatment arm; importantly, this cutoff also corresponds with
established age classifications applied to patients with cancer [22,23].
While 70 years is also often used as the threshold for clinical trials in
elderly patients [24,25], in CheckMate 141, patient numbers with this
cutoff were too small for meaningful analyses. Nivolumab therapy re-
sulted in an OS benefit compared with IC and responses were durable in
patients with recurrent/metastatic SCCHN across both age groups
of< 65 and ≥65 years old at a minimum follow-up of 2 years. Among
patients ≥65 years old in the nivolumab arm, ORR was 14.7% with 10
patients experiencing complete or partial responses. The median OS for
this subgroup was 6.9months and 13.0% of patients were still alive at
30months, nearly triple that of patients in the IC arm. Although the
number of patients≥70 years old was limited (31 in the nivolumab arm
and 23 in the IC arm), the efficacy and safety of nivolumab in these
patients were consistent with results seen in patients ≥65 years old.
These data in the elderly population of CheckMate 141 are com-
parable to those previously reported in the primary analysis and 2-year
update to the study [14,15]. At 2 years, the ORR for patients receiving
nivolumab was 13.3%; median OS was 7.7months with 16.9% of pa-
tients still alive at 24months [15]. OS benefit was maintained with
nivolumab irrespective of tumor PD-L1 expression levels and HPV
status, and this finding is consistent with results presented in the cur-
rent analysis across age groups. Even though no clear difference could
be observed in patients ≥65 years without PD-L1–expressing tumors,
the number of patients in this subgroup was small. Results were re-
cently published from the phase 3 KEYNOTE-040 study comparing
pembrolizumab versus methotrexate, docetaxel or cetuximab [13].
Age-related immune dysfunction, attributed to both cellular com-
ponents of the immune system as well as changes in the tumor micro-
environment, is a key challenge in developing effective im-
munotherapies for elderly patients [26,27]. Immunosenescence is
thought to impair the antitumor immune response through reduced
tumor antigen release, altered antigen-uptake and antigen-presenting
functions, and impaired T-cell activation and trafficking, all of which
can hinder the elimination of tumor cells [28]. However, tumor mu-
tational burden, which has been shown to increase with age, among
other factors, leads to increased neoantigen formation and subsequent
increased immune response [29]. The greater immunogenicity of tu-
mors with high tumor mutational burden makes them a target for im-
muno-oncology therapies [30,31]. Advanced age may also exacerbate
treatment-related toxicities due to metabolic changes, polypharmacy,
and comorbidities [32], thereby limiting therapeutic options. A higher
prevalence of adverse events such as nephrotoxicity, thrombocyto-
penia, and myelosuppression is associated with chemotherapy in el-
derly patients [33,34]. In contrast, nivolumab was well tolerated in the
current study, and the incidence and severity of TRAEs were compar-
able among patients in both age groups. The most common associated
adverse events in patients ≥65 years old were fatigue, decreased ap-
petite, and diarrhea, similar to those reported in the overall study po-
pulation [14,15].
Fig. 3. Progression-free survival (PFS) in patients (A)< 65 years old and (B) ≥65 years old. Abbreviations: CI= confidence interval; HR=hazard ratio;
IC= investigator’s choice; NIVO=nivolumab.
Table 2
Best overall response per investigator. Abbreviations: + = censored value; CI= confidence interval; IC= investigator’s choice; NR=not reached; ORR=objective
response rate.
< 65 Years ≥65 Years
Nivolumab (n=172) IC (n= 76) Nivolumab (n=68) IC (n=45)
Best overall response, n (%)
Complete response 4 (2.3) 0 3 (4.4) 1 (2.2)
Partial response 18 (10.5) 5 (6.6) 7 (10.3) 1 (2.2)
Stable disease 36 (20.9) 31 (40.8) 19 (27.9) 12 (26.7)
Progressive disease 72 (41.9) 25 (32.9) 27 (39.7) 17 (37.8)
Unable to determine 42 (24.4) 15 (19.7) 12 (17.6) 14 (31.1)
ORR, n (%) 22 (12.8) 5 (6.6) 10 (14.7) 2 (4.4)
[95% CI] [8.2–18.7] [2.2–14.7] [7.3–25.4] [0.5–15.1]
Time to objective response among responders, median (range), mo 2.1 (1.8–7.4) 2.0 (1.9–2.0) 2.1 (1.8–6.3) 3.5 (2.3–4.6)
Duration of response among responders, median (range), mo 8.5 (2.8 to 28.0+) 3.0 (2.7+ to 11.3) NR (2.8 to 32.8+) 4.9 (1.5+to 4.9)
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A meta-analysis was recently published using random-effects esti-
mates to evaluate the efficacy of PD-1 and PD-L1 inhibitors in patients
≥65 years old with advanced solid tumors, including clinical studies of
nivolumab in non-small cell lung cancer, renal cell carcinoma, and
melanoma [35]. Similar to the results of the current analysis, a con-
sistent improvement in survival associated with the use of these
therapies across groups of younger and older patients was reported. A
retrospective study of PD-1 and PD-L1 inhibitors in patients with mel-
anoma also found no significant differences in toxicity between younger
and older age groups, although there was a trend toward a higher rate
of endocrine-related events in elderly patients [11].
The current analysis addresses an unmet need for data among
elderly patients with SCCHN. Elderly patients are often under-
represented in clinical trials [2,36,37], which contributes to this in-
creasing need given the changing demographics of head and neck
cancer. In clinical trials specific to elderly patients, treatment selection
is often based on fitness or geriatric evaluation as frailty can vary
among patients considered to be elderly [24,37–39]. The current study
did not assess frailty before enrollment; however, patients randomized
to the IC arm of this study were considered able and fit to undergo
chemotherapy (including taxane) or treatment with cetuximab. While
limited by the post hoc nature of the analysis, our results highlight the
opportunity for new interventions to improve outcomes and minimize
toxicities in elderly patients with SCCHN.
Fig. 4. Best reduction from baseline in target lesions in patients (A)< 65 years old and (B)≥65 years old. Abbreviation: *= responders; square symbol = % change
truncated to 100%; IC= investigator’s choice.
Table 3
Treatment-related adverse events (TRAEs) in ≥10% of patients. Abbreviation: IC= investigator’s choice.
< 65 Years ≥65 Years
Nivolumab (n=168) IC (n=71) Nivolumab (n= 68) IC (n= 40)
Any Grade Grade 3–4 Any Grade Grade 3–4 Any Grade Grade 3–4 Any Grade Grade 3–4
Any TRAE, n (%) 107 (63.7) 27 (16.1) 55 (77.5) 22 (31.0) 39 (57.4) 9 (13.2) 33 (82.5) 19 (47.5)
Fatigue 24 (14.3) 3 (1.8) 14 (19.7) 1 (1.4) 13 (19.1) 2 (2.9) 6 (15.0) 2 (5.0)
Nausea 17 (10.1) 0 16 (22.5) 1 (1.4) 5 (7.4) 0 7 (17.5) 0
Rash 14 (8.3) 0 1 (1.4) 0 5 (7.4) 0 4 (10.0) 1 (2.5)
Diarrhea 13 (7.7) 1 (0.6) 7 (9.9) 1 (1.4) 7 (10.3) 0 9 (22.5) 1 (2.5)
Decreased appetite 11 (6.5) 0 6 (8.5) 0 8 (11.8) 0 2 (5.0) 0
Anemia 8 (4.8) 2 (1.2) 13 (18.3) 3 (4.2) 4 (5.9) 1 (1.5) 6 (15.0) 3 (7.5)
Asthenia 8 (4.8) 0 12 (16.9) 2 (2.8) 2 (2.9) 1 (1.5) 5 (12.5) 0
Vomiting 6 (3.6) 0 4 (5.6) 0 2 (2.9) 0 4 (10.0) 0
Mucosal inflammation 4 (2.4) 0 9 (12.7) 1 (1.4) 0 0 6 (15.0) 1 (2.5)
Stomatitis 2 (1.2) 1 (0.6) 8 (11.3) 2 (2.8) 4 (5.9) 0 4 (10.0) 1 (2.5)
Alopecia 0 0 10 (14.1) 0 0 0 4 (10.0) 0
N.F. Saba, et al. Oral Oncology 96 (2019) 7–14
12
Conclusion
Here, we show that nivolumab therapy demonstrated efficacy ben-
efit, durable response, and a manageable safety profile in patients
≥65 years old with SCCHN, suggesting that age should not be a critical
factor when selecting second-line immunotherapy. These data support
the use of nivolumab in younger and older patients with recurrent/
metastatic SCCHN post-platinum therapy.
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